drugset / Trial / NCT02086968
Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be inappropriate for oral iron therapy.
Timeline
- Start
- 2014-01-01
- Primary completion
- 2016-07-16
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ferric carboxymaltose | Other / unclassified | 15 mg/kg | Intravenous |
| Comparator | Ferrous Sulfate | Diagnostic / imaging agent | 325 mg | Oral |